Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
The emergence of new infections in India is a growing concern
Subscribe To Our Newsletter & Stay Updated
